Insulet Q1 FY26: where the revenue came from and where it went
The whole income statement of Insulet for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jan 1 – Mar 31, 2026
- Reported
- May 6, 2026
Revenue$0.76B
+34% year over year
Gross profit$0.53B
69% margin
Operating profit$0.12B
16% margin
Net profit$0.09B
12% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 0.76 | 100% | +34% |
| U.S.Omnipod | 0.52 | 68% | +28% |
| International omnipod | 0.24 | 32% | +59% |
| Drug delivery | <0.01 | 0% | −78% |
| Cost of revenue | −0.23 | 31% | |
| Gross profit | 0.53 | 69% margin | −2pp |
| R&D | −0.09 | 12% | +1pp |
| SG&A | −0.32 | 41% | −4pp |
| Operating profit | 0.12 | 16% margin | +0pp |
| Interest & other costs | −0.01 | ||
| Tax | −0.02 | ||
| Net profit | 0.09 | 12% margin | +6pp |
129 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest